Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer

Loading...
Loading...
  • The Journal of Clinical Oncology has published results from Deciphera Pharmaceuticals Inc DCPH INTRIGUE Phase 3 study of Qinlock (ripretinib) for advanced gastrointestinal stromal tumor (GIST) previously treated with Novartis AG's NVS Gleevec/Glivec (imatinib). 
  • Although Qinlock did not offer a statistically significant improvement in progression-free survival (PFS) compared to sunitinib, the drug showed meaningful clinical activity with fewer Grade 3/4 treatment-emergent adverse events and improved tolerability.
  • In addition, Qinlock had a more favorable safety profile than Pfizer Inc's PFE Sutent (sunitinib), with fewer Grade 3/4 adverse events.
  • Patients in the Qinlock arm reported less deterioration in role functioning and better outcomes than sunitinib.
  • In patients with a KIT exon 11 primary mutations, ripretinib demonstrated a median PFS (mPFS) of 8.3 months compared to 7.0 months for the sunitinib arm. 
  • In the intention-to-treat (ITT) population, ripretinib demonstrated an mPFS of 8.0 months vs. 8.3 months.
  • In patients with a KIT exon 11 primary mutations, ripretinib demonstrated an objective response rate of 23.9% vs. 14.6%, and 21.7% vs. 17.6% in the ITT populations.
  • The FDA has approved Qinlock for advanced GIST patients who have received prior treatment with three or more kinase inhibitors.
  • Price Action: DCPH shares traded 3.66% lower at $16.57 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...